ENTX · NASDAQ
Entera Bio (ENTX) Stock Price & Fundamentals
Entera Bio (ENTX) closed at $1,001.99 on Oct 9, 2026, down 1.03% from the previous close of $1,012.37.
Share price, past year
1Y +29.44%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,001.99 |
| Sep 30, 2026 | $1,017.51 |
| Aug 31, 2026 | $996.00 |
| Jul 31, 2026 | $918.17 |
| Jun 30, 2026 | $962.67 |
| May 29, 2026 | $902.00 |
| Apr 30, 2026 | $863.37 |
| Mar 31, 2026 | $861.51 |
| Feb 27, 2026 | $863.15 |
| Jan 30, 2026 | $842.71 |
| Dec 31, 2025 | $773.51 |
| Nov 28, 2025 | $765.28 |
| Oct 31, 2025 | $797.92 |
Key statistics
- Market cap
- $49.39B
- P/E (TTM)
- 2,947.0
- EPS (TTM)
- $0.34
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$17.03M
- Shares outstanding
- 49.3M
- Dividend yield
- —
- 52-week range
- $742.13 – $1,041.99
Entera Bio's market cap is $49.39B, based on a share price of $1,001.99 and 49.3M shares outstanding as of Jun 30, 2026.
Financials
Entera Bio reported revenue of $42.00K for fiscal 2025, down 76.80% from fiscal 2024.
Entera Bio reported a net loss of $11.44M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $42.00K | −76.8% | −$11.44M | −27,235.7% | $0.25 | −$7.48M |
| FY2024ended Dec 31, 2024 | $181.00K | — | −$9.54M | −5,271.3% | $0.25 | −$6.82M |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$8.89M | — | $0.31 | −$7.33M |
| FY2022ended Dec 31, 2022 | $134.00K | −76.5% | −$13.07M | −9,754.5% | $0.45 | −$12.55M |
| FY2021ended Dec 31, 2021 | $571.00K | +56.4% | −$12.19M | −2,134.3% | $0.47 | −$9.08M |
| FY2020ended Dec 31, 2020 | $365.00K | — | −$11.22M | −3,072.9% | $0.67 | −$10.61M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$7.31M | $0.14 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$3.51M | $0.07 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$3.02M | $0.06 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$3.20M | $0.07 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$2.66M | $0.06 |
| Q1 FY2025ended Mar 31, 2025 | $42.00K | −$2.57M | $0.06 |
| Q4 FY2024ended Dec 31, 2024 | $82.00K | −$2.36M | $0.06 |
| Q3 FY2024ended Sep 30, 2024 | $42.00K | −$3.02M | $0.08 |
Company profile
- Name
- Entera Bio Ltd.
- Ticker
- ENTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, 9112002
- Incorporated in
- L3
- Fiscal year ends
- December
- SEC CIK
- 0001638097
Recent SEC filings
- Oct 6, 2026
- Aug 18, 2026
- Aug 7, 2026
- Aug 7, 2026
- Jul 28, 2026
- Jul 16, 2026
- May 8, 2026
- May 8, 2026
Frequently asked questions
What is Entera Bio's stock price?
Entera Bio (ENTX) closed at $1,001.99 on Oct 9, 2026, down 1.03% from the previous close of $1,012.37.
What is Entera Bio's market cap?
Entera Bio's market cap is $49.39B, based on a share price of $1,001.99 and 49.3M shares outstanding as of Jun 30, 2026.
How much revenue does Entera Bio make?
Entera Bio reported revenue of $42.00K for fiscal 2025, down 76.80% from fiscal 2024.
What is ENTX's P/E ratio?
Entera Bio's price-to-earnings ratio is 2,947.0, based on trailing twelve-month diluted EPS of $0.34.
Does Entera Bio pay a dividend?
Entera Bio's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Entera Bio Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures